Follow
Shlomo Keidar
Shlomo Keidar
Skeidar@rambam.health.gov.il
Verified email at rambam.health.gov.il
Title
Cited by
Cited by
Year
ACE2 of the heart: from angiotensin I to angiotensin (1–7)
S Keidar, M Kaplan, A Gamliel-Lazarovich
Cardiovascular research 73 (3), 463-469, 2007
3592007
Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a …
U Milman, S Blum, C Shapira, D Aronson, R Miller-Lotan, Y Anbinder, ...
Arteriosclerosis, thrombosis, and vascular biology 28 (2), 341-347, 2008
3542008
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the …
S Keidar, M Kaplan, E Pavlotzky, R Coleman, T Hayek, S Hamoud, ...
Circulation 109 (18), 2213-2220, 2004
3082004
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients
S Keidar, A Gamliel-Lazarovich, M Kaplan, E Pavlotzky, S Hamoud, ...
Circulation research 97 (9), 946-953, 2005
2512005
Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its …
O Hussein, S Schlezinger, M Rosenblat, S Keidar, M Aviram
Atherosclerosis 128 (1), 11-18, 1997
2151997
Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins
S Keidar, M Kaplan, A Hoffman, M Aviram
Atherosclerosis 115 (2), 201-215, 1995
2061995
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy
M Aviram, O Hussein, M Rosenblat, S Schlezinger, T Hayek, S Keidar
Journal of cardiovascular pharmacology 31 (1), 39-45, 1998
1941998
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent …
T Hayek, J Attias, R Coleman, S Brodsky, J Smith, JL Breslow, S Keidar
Cardiovascular research 44 (3), 579-587, 1999
1891999
Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes
B Fuhrman, L Koren, N Volkova, S Keidar, T Hayek, M Aviram
Atherosclerosis 164 (1), 179-185, 2002
1842002
Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
H Osamah, R Mira, S Sorina, K Shlomo, A Michael
British journal of clinical pharmacology 44 (1), 77-84, 1997
1821997
The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice
S Keidar, J Attias, J Smith, JL Breslow, T Hayek
Biochemical and biophysical research communications 236 (3), 622-625, 1997
1771997
Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6
S Keidar, R Heinrich, M Kaplan, T Hayek, M Aviram
Arteriosclerosis, thrombosis, and vascular biology 21 (9), 1464-1469, 2001
1702001
Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E–deficient mice
S Keidar, T Hayek, M Kaplan, E Pavlotzky, S Hamoud, R Coleman, ...
Journal of cardiovascular pharmacology 41 (6), 955-963, 2003
1572003
Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice
T Hayek, J Attias, J Smith, JL Breslow, S Keidar
Journal of cardiovascular pharmacology 31 (4), 540-544, 1998
1471998
A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice
R Coleman, T Hayek, S Keidar, M Aviram
Acta histochemica 108 (6), 415-424, 2006
1442006
Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events
D Baldassarre, M Amato, L Pustina, S Castelnuovo, S Sanvito, L Gerosa, ...
Atherosclerosis 191 (2), 403-408, 2007
1272007
Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for …
S Keidar, M Kaplan, C Shapira, JG Brook, M Aviram
Atherosclerosis 107 (1), 71-84, 1994
1271994
Angiotensin, LDL peroxidation and atherosclerosis
S Keidar
Life sciences 63 (1), 1-11, 1998
1231998
Lesioned low-density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated
M Aviram, I Maor, S Keidar, T Hayek, J Oiknine, Y Barel, Z Adler, ...
Biochemical and biophysical research communications 216 (2), 501-513, 1995
1211995
Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis
S Keidar, J Attias, R Heinrich, R Coleman, M Aviram
Atherosclerosis 146 (2), 249-257, 1999
1201999
The system can't perform the operation now. Try again later.
Articles 1–20